Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent regulation of tumor growth. Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent.

Slides:

Advertisements

Similar presentations

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

Advertisements

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

Cytokine and chemokine expression of flucloxacillin-specific T cell clones (TCC) of patient P1. Cytokine and chemokine expression of flucloxacillin-specific.

Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

Tumor development of poorly immunogenic LLC and B16F10 cells modified to produce GM-CSF was markedly inhibited. Tumor development of poorly immunogenic.

IL-6 is dispensable for the suppressive activity of MDSC on primary CD4+ T-cell activation. IL-6 is dispensable for the suppressive activity of MDSC on.

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Functions of myeloid cells.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. MC38.

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

Exosome-mediated inhibition of T cells is reversible.

Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell depletion. Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell.

M-MDSC:mast cell cross-talk in the regulation of TNFα production.

Mice immunized twice with RRBC showed superior protection to tumor challenge with αGal-positive MC38 colon carcinoma cells compared with mock-immunized.

CD8 T cells play a critical role in responses of TILs due to BRAF inhibition. CD8 T cells play a critical role in responses of TILs due to BRAF inhibition.

In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s

Reduced tumor growth in CCR5-deficient mice is associated with perturbed killing ability of Treg cells. Reduced tumor growth in CCR5-deficient mice is.

coTCRcys-transduced T cells control tumor growth in vivo.

Antitumor activity of KM100+5 μmol/L MTX treatment in the presence or absence of CD8+ T cells in BALB-neuT mice bearing subcutaneous tumors of TUBO cells.

The selective depletion of DTR-expressing FAP+/CD45+ and FAP+/CD45− tumoral cells from bone marrow chimeric mice by the administration of DTX. A, sketch.

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

In vivo thrombosis of tumor vasculature.

Anti-Flk-1 mAb treatment reduces vessel density in tumors.

Experimental metastasis inhibition by primary tumors is mediated by NK cells and IFNγ. Experimental metastasis inhibition by primary tumors is mediated.

Anti-Flk-1 mAb inhibits vascularization of Matrigel plugs.

PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.

Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3.

PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. A, 4T1/HAS3.

ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells, and NK cells. ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells,

5FU-induced specific activation of CD8+ T cells.

CDN–treated MOC1 tumors demonstrate enhanced activation of innate and antigen-specific adaptive immunity. CDN–treated MOC1 tumors demonstrate enhanced.

MEDI4736 shows antitumor activity in xenograft mouse models of human cancer. MEDI4736 shows antitumor activity in xenograft mouse models of human cancer.

Dual blockade of PD-1 and CTLA-4 directly activates CD4+Foxp3− cells in the absence of CD8+ or CD4+Foxp3+ cells. Dual blockade of PD-1 and CTLA-4 directly.

Combination CDN and PD-L1 mAb treatment of established MOC1 tumors produces consistent tumor rejection. Combination CDN and PD-L1 mAb treatment of established.

Influenza vaccine enhances NK cell function through IFN-α.

Essential role for the overexpression of type I IFN-related genes in the improved chemotherapeutic response of Stat3−/− tumors. Essential role for the.

HMQ1611 inhibited breast tumor growth in mice.

DAC treatment alters immune cell composition and enhances cytokine production in the peritoneal lavage. DAC treatment alters immune cell composition and.

Deletion of Tgfbr2 in myeloid cells elevated IFN-γ production in CD8+ T cells, and systemic IFN-γ neutralization diminished metastasis inhibition in Tgfbr2MyeKO.

Immunophenotypic analysis of TILs in B16 and K1735 melanoma following combination therapy with antibodies targeting PS and PD-1. Immunophenotypic analysis.

Anti-SEMA4D antibody regulates immune-cell infiltration and inhibits growth of Tubo.A5 orthotopic mammary carcinoma. Anti-SEMA4D antibody regulates immune-cell.

Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.

Expression of HO-1 by the FAP+/F4/80+ tumoral macrophages.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Increased expression of angiogenic factors and inflammatory cytokines in mice exposed to hypoxia. Increased expression of angiogenic factors and inflammatory.

Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

The effect of TGFβ on the post-RT increase of Tregs in tumors.

PDL192 and inhibit the growth of xenograft tumors.

LSECtin, expressed by B16 cells, inhibits the tumor-specific immune responses both in vivo and in vitro. LSECtin, expressed by B16 cells, inhibits the.

Antibody-mediated blockade of the immune-inhibitory PD-1–PD-L1 signaling pathway prolongs survival in poly(I:C)-treated mice. Antibody-mediated blockade.

ADU-S100 primes the innate immune system in tolerant, tumor bearing neu/N mice. ADU-S100 primes the innate immune system in tolerant, tumor bearing neu/N.

Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. A,

TNFα-expanded MRD cells acquire the recurrence-competent phenotype.

The effect of βAR signaling on the generation of a cytotoxic CD8+ T-cell response in vivo. The effect of βAR signaling on the generation of a cytotoxic.

Ceritinib is a potent ALK inhibitor in crizotinib-naïve models.

Lnc-C/EBPβ negatively regulates immune-suppressive function of MDSCs in vivo. Lnc-C/EBPβ negatively regulates immune-suppressive function of MDSCs in vivo.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

TAMs upregulate DNMT1 in gastric cancer cells through the CCL5/CCR5/STAT3 pathway. TAMs upregulate DNMT1 in gastric cancer cells through the CCL5/CCR5/STAT3.

Presentation transcript:

Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent regulation of tumor growth. Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent regulation of tumor growth. A, C57BL/6 mice bearing established, nonimmunogenic LL2 or immunogenic LL2/OVA tumors, and Rag2−/− mice with LL2/OVA tumors were treated with daily administration of SnMP (25 μmol/kg) or vehicle control, with the arrow denoting the initiation of treatment. B and C, mice bearing established LL2/OVA tumors were treated with SnMP (25 μmol/kg) or vehicle for 24 hours after which the change in tumor volumes (B) and the expression of TF by CD31+ endothelial cells were measured (C). D, mice bearing LL2/OVA tumors that had been pretreated with neutralizing anti-TNF-α and anti-IFN-γ antibodies or with isotype control antibody were given SnMP (25 μmol/kg) or vehicle, and tumor volumes were measured 24 hours later. The curves describing tumor growth in A were compared for differences using the “CompareGrowthCurves” permutation test. ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001. James N. Arnold et al. Cancer Immunol Res 2014;2:121-126 ©2014 by American Association for Cancer Research